 |
市場調查報告書
商品編碼
2075440
肉瘤治療市場：按療法、肉瘤類型、最終用戶和地區分類Sarcoma Treatment Market, By Treatment Type, By Sarcoma Type, By End User, By Geography |
||||||
價格
簡介目錄
預計到 2026 年，肉瘤治療市場規模將達到 50.7 億美元，到 2033 年將達到 85.7 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 7.8%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 50.7億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 7.80% | 預計金額（2033 年） | 85.7億美元 |
全球肉瘤治療市場涵蓋多種治療類別，包括標靶治療、化療和免疫療法，用於治療軟組織肉瘤、骨癌（其中骨癌最為常見）和胃腸道基質腫瘤（GIST）等疾病。醫院和專科診所的廣泛應用以及對更有效率、更可靠解決方案的需求是推動市場成長的主要因素。持續的技術進步和終端用戶需求的不斷成長是推動該市場發展的關鍵因素。
市場動態：
軟組織肉瘤（尤其是骨癌）治療領域應用範圍的擴大、終端用戶需求的成長以及對提高效率和性能的持續關注，預計將成為全球肉瘤治療市場成長的主要驅動力。更多樣化的選擇也使得更多用戶能夠獲得這些解決方案。
例如，各公司正在拓展產品系列，以滿足醫院和專科診所不斷變化的需求。此外，預計在預測期內，加大對創新和新技術整合的投資，將為市場參與者創造新的成長機會。
本報告的主要特點
- 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
- 本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）對全球肉瘤治療市場的主要公司進行介紹。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
- 《全球肉瘤治療市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球肉瘤治療市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 企業合併、商業夥伴關係
- 監管趨勢
- 主要進展
- PEST分析
- 夥伴關係方案
- 品牌和定價分析
- 銷售代理情況
- 波特五力分析
- 技術進步
- 主要進展
- 市場趨勢
- 前景
- 主要公司：按銷售收入
第4章 肉瘤治療市場：依治療方法分類（2026-2033 年）
- 標靶治療
- 化療
- 免疫療法
- 放射線治療
- 外科手術
- 其他
第5章 肉瘤治療市場：依肉瘤類型分類（2026-2033 年）
- 軟組織肉瘤
- 骨癌
- 胃腸道基質腫瘤（GIST）
- 卡波西氏肉瘤
- 其他
第6章 肉瘤治療市場：依最終使用者分類（2026-2033 年）
- 醫院
- 專科診所
- 門診手術中心
- 研究機構
- 其他
第7章 肉瘤治療市場：依地區分類（2026-2033 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
- 亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
- 中東和非洲
- 巴林
- 科威特
- 阿曼
- 卡達
- 沙烏地阿拉伯
- UAE
- 以色列
- 南非
- 北非
- 中非
- 其他中東國家
第8章 競爭情勢
- Bristol-Myers Squibb
- Roche Holding AG
- Daiichi Sankyo Company, Limited
- Astellas Pharma Inc.
- Epizyme, Inc.
- Blueprint Medicines Corporation
- PharmaMar SA
- Incyte Corporation
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
第9章
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI3537
Sarcoma Treatment Market is estimated to be valued at USD 5.07 billion in 2026 and is expected to reach USD 8.57 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.07 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.80% | 2033 Value Projection: | USD 8.57 billion |
The global sarcoma treatment market covers a broad set of treatment type categories, including Targeted Therapy, Chemotherapy, and Immunotherapy, used across applications such as Soft Tissue Sarcoma, Bone Sarcoma (Osteosarcomadominates), and Gastrointestinal Stromal Tumor (GIST). Demand is supported by adoption among Hospitals, and Specialty Clinics and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Soft Tissue Sarcoma, and Bone Sarcoma (Osteosarcomadominates), rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global sarcoma treatment market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across Hospitals, and Specialty Clinics. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global sarcoma treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Bristol-Myers Squibb, Roche Holding AG, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., Epizyme, Inc., Blueprint Medicines Corporation, PharmaMar S.A., Incyte Corporation, Amgen Inc., and Takeda Pharmaceutical Company Limited, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global sarcoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sarcoma treatment market.
Detailed Segmentation:
- Global Sarcoma Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Others
- Global Sarcoma Treatment Market, By Sarcoma Type (Revenue, USD Bn, 2021 - 2033)
- Soft Tissue Sarcoma
- Bone Sarcoma (Osteosarcomadominates)
- Gastrointestinal Stromal Tumor (GIST)
- Kaposis Sarcoma
- Others
- Global Sarcoma Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Research Institutes
- Ambulatory Surgical Centers
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Bristol-Myers Squibb*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Roche Holding AG
- Daiichi Sankyo Company, Limited
- Astellas Pharma Inc.
- Epizyme, Inc.
- Blueprint Medicines Corporation
- PharmaMar S.A.
- Incyte Corporation
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- tAssumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Sarcoma Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Sarcoma Treatment Market By Treatment Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Radiation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Surgery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Sarcoma Treatment Market By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Soft Tissue Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Bone Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Gastrointestinal Stromal Tumor (GIST)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Kaposi's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Sarcoma Treatment Market By End User, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Research Institute
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Sarcoma Treatment Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Sarcoma Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
8. Competitive Landscape
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Epizyme, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Blueprint Medicines Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- PharmaMar S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Incyte Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
